首页> 外文OA文献 >PCN39 Potential Time and Cost Savings with Herceptin (Trastuzumab) Subcutaneous (SC) Injection Versus Herceptin Intravenous (IV) Infusion: Results from Three Different English Patient Settings

【2h】

PCN39 Potential Time and Cost Savings with Herceptin (Trastuzumab) Subcutaneous (SC) Injection Versus Herceptin Intravenous (IV) Infusion: Results from Three Different English Patient Settings

机译：赫赛汀（曲妥珠单抗）皮下（SC）注射与赫赛汀静脉（IV）输注相比PCN39潜在的时间和成本节省：来自三种不同英国患者设置的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Samanta K.; Moore L.; Jones G.; Evason J.; Owen G.;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit [J] . Wiebren A.A. Tjalma, Tom Van den Mooter, Tim Mertens, European Journal of Obstetrics, Gynecology and Reproductive Biology: An International Journal . 2018,第期

机译：皮下曲据（Herceptin）与静脉内曲妥珠单抗治疗Her2阳性乳腺癌的患者：瘦营运日保健肿瘤学单位的时间，运动和成本评估研究
2. COST SAVINGS WITH HERCEPTIN (R) (TRASTUZUMAB) SC VS IV ADMINISTRATION: A TIME & MOTION STUDY [J] . The Breast : . 2013,第Suppla1期

机译：赫赛汀（TRASTUZUMAB）SC VS IV的成本节省：时间和动作研究
3. Subcutaneous Trastuzumab (Herceptin?): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer [J] . Russell Burcombe, Steve Chan, Richard Simcock, Advances in Breast Cancer Research . 2013,第4期

机译：皮下曲妥珠单抗（赫赛汀（Herceptin？））：英国时间和运动研究与静脉内制剂治疗HER2阳性早期乳腺癌患者的比较
4. TROIKA‐1: A double‐blind randomized parallel group study aimed to demonstrate the equivalent pharmacokinetic profile of HD201 a potential biosimilar candidate to trastuzumab versus EU‐Herceptin® and US‐Herceptin® in healthy male subjects [O] . Martin Demarchi, Pierre Coliat, Kristi Mclendon, 2021

机译：Troika-1：一种双盲随机并行组旨在证明HD201的等同药代动力学谱潜在的生物仿制物候选者对曲妥珠单抗与Eu-Herceptin®和Us-herceptin®在健康的男性主题中
5. PCN103 - PREDICTED TREATMENT COSTS AND SAVINGS PER PATIENT OF KANJINTI® (TRASTUZUMAB BIOSIMILAR) VS. SUBCUTANEOUS (SC) AND INTRAVENOUS (IV) HERCEPTIN® AND OTHER TRASTUZUMAB BIOSIMILARS IN ITALY [O] . I. Agirrezabal, I. Gaikwad, L. Cirillo, 2018

机译：PCN103 - 每位患者的kanjinti®（Trastuzumab BioSimilar）的预测治疗成本和节省）与皮下（SC）和静脉注射（IV）Herceptin®和其他意大利的Trastuzumab生物纤维单模

PCN39 Potential Time and Cost Savings with Herceptin (Trastuzumab) Subcutaneous (SC) Injection Versus Herceptin Intravenous (IV) Infusion: Results from Three Different English Patient Settings

著录项

相似文献

相关主题

期刊订阅